Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2015-06-10 Regulatory Filings
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
FDA godkänner en medium tablettstyrka (2,9 mg/0,71 mg) av Zubsolv®
Regulatory Filings Classification · 1% confidence The document is a press release ("Pressmeddelande") announcing that the FDA has approved a new medium tablet strength (2.9 mg/0.71 mg) of the drug Zubsolv®. This announcement details a regulatory milestone (FDA approval) and provides updates on product portfolio expansion and launch timelines. This type of announcement, which is a specific update on a product or regulatory event rather than a comprehensive financial report (like 10-K or IR) or a general regulatory filing fallback (RNS), fits best under the category for Capital/Financing Updates (CAP) if it were about fundraising, or more generally, a Regulatory Filing (RNS) if no other category fits. However, since it is a specific announcement about a regulatory approval impacting the product offering, and it is not a standard financial report, it is best classified as a general Regulatory Filing (RNS) as it is a specific, non-financial regulatory update that doesn't fit the other specific categories like DIRS, DIV, or MANG. Given the options, RNS serves as the best catch-all for specific regulatory news that isn't a core financial report or management change. The document length (4255 chars) is substantial enough that it is not just a brief announcement of an attached report (RPA).
2015-06-10 Swedish
Number of shares and votes in Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release announcing a change in the total number of shares and votes in Orexo AB due to the exercise of warrants. This directly relates to the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers changes in the number of shares. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about the share count changing, SHA is the most appropriate code.
2015-05-29 English
Antal aktier och röster i Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release (1415 characters) dated May 29, 2015, titled 'Antal aktier och röster i Orexo' (Number of shares and votes in Orexo). It explicitly states that the total number of shares and votes has changed due to the exercise of warrants and provides the new total count (34,399,723). This directly relates to a change in the company's capital structure or share count. This fits the definition of 'Share Issue/Capital Change' (SHA) better than a general regulatory filing (RNS) or a dividend notice (DIV). It is not a report itself, but a notification of a change in share count.
2015-05-29 Swedish
Orexo presenterar på Redeye Investor Forum i Göteborg
Regulatory Filings Classification · 1% confidence The document is a short announcement from Orexo stating that the CEO will present the company at the 'Redeye Investor Forum' on May 7, 2015. It provides details about the event and mentions where the presentation material will be available after the event. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing about results (ER) or management changes (MANG). It is an announcement about the company's participation in an investor event, which aligns best with an Investor Presentation (IP) announcement or, given the context of announcing participation in an external forum, it could be considered a general announcement. However, since the core purpose is to inform investors about an upcoming presentation where company information will be shared, 'Investor Presentation' (IP) is the most fitting category, even though it's an announcement *about* a presentation rather than the presentation itself. Given the short length and the focus on an upcoming investor event, it is classified as IP.
2015-05-06 Swedish
Orexo divests subsidiary Kibion
M&A Activity Classification · 1% confidence The document is a press release announcing the divestment (sale) of a subsidiary, Kibion AB, by the parent company, Orexo AB. This action involves a significant corporate transaction, specifically a change in asset ownership or structure, which falls under the scope of M&A activity or major corporate restructuring. Reviewing the definitions, 'M&A Activity (Code: TAR)' covers merger proposals or takeover bids. While this is a divestment, it is the opposite side of an acquisition and represents a major transaction impacting the corporate structure. Since there is no specific code for 'Divestment Announcement,' TAR (M&A Activity) is the most appropriate fit among the provided options for a significant transaction like selling a subsidiary. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS) because it details a specific strategic business event.
2015-04-30 English
Orexo avyttrar dotterbolaget Kibion
M&A Activity Classification · 1% confidence The document is a press release announcing the divestiture (sale) of a subsidiary, Kibion AB, by the parent company, Orexo AB. This action directly relates to changes in the company's structure, assets, and strategic focus (shifting back to Zubsolv). This type of announcement, concerning a significant corporate transaction like a sale of a business unit, falls under the category of corporate financing or structural changes. While it is not explicitly a 'Merger or Acquisition' (TAR) of the acquiring entity, it is a major transaction affecting capital structure and business scope. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it describes a major change in the company's asset base and strategic direction, often announced via press release. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS) without a more specific category. The document length (3339 chars) suggests it is the primary announcement, not just a notification of publication (RPA).
2015-04-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.